Study S001034

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

ClinicalTrials.gov record

Registration

Registration: NCT01766245
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 28
Start: 2012-12
Primary completion: 2013-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-002212-20; OTHER:U1111-1130-3931

Registered primary outcomes

Area under the plasma semaglutide concentration curve [0-4 weeks after a single dose s.c. semaglutide administration]
Cmax, the maximum plasma semaglutide concentration [20-40 hours after a single dose s.c. semaglutide administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.